ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1646

A Study Comparing Rituximab and Modified Ponticelli (MP) Regimen in Primary Membranous Nephropathy(PMN)

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Kumar, Abhishek, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
  • Ray Chaudhury, Arpita, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
  • Gupta, Saugat Das, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
  • Mukherjee, Sriranjan, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
  • Sengupta, Moumita, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India

Group or Team Name

  • IPGMER Nephrology
Background

The study was designed in December 2018 when the Gemritux trial had established Rituximab as an alternative to MP regimen in the treatment of PMN.So we designed a study comparing Rituximab and MP Regimen.

Methods

We allocated 35 adults with PMN and proteinuria >3.5 gm/day in a 3:2 ratio to MPregimen or Rituximab 375mg/m2 on days 1,8,15 and 22.The primary outcome was complete or partial remission(CR+PR)at 6 and 12 months in the 2 groups.The other findings included trends of 24 hr urine protein,albumin,creatine and seriousadverse events at 6 and 12 months in both groups.

Results

At 6 months,12 of 21 patients (57.14%) allocated to MP Regimen and 5 of 14 patients (35.71%) allocated to Rituximab experienced remission(CR+PR) (odds ratio [OR], 2.4; 95% CI, 0.596 -9.670,p value 0.10).At 12 months, 14 of 21 patients (66.66%) allocated to MP Regimen and 10 of 14 patients (71.43%) allocated to Rituximab experienced remission(CR+PR) (odds ratio [OR], 0.8; 95%CI,0.184-3.487,p value 0.383).Serious adverse events occurred in 15% of patients receiving Rituximab and in 24% receiving the MP Regimen.

Conclusion

We found No Statistically Significant difference betweenRituximab and the Modified Ponticelli Regimen in the treatment of membranous nephropathy . A head-to-head, longer follow up study comparing MP Regimen versus Rituximab is required in terms of duration of remission and side effect profile between the two treatment groups.

Time To Remission Analysis

Funding

  • Government Support – Non-U.S.